NORCROSS, Ga., April 11 /PRNewswire-FirstCall/ -- Immucor, Inc. , the global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that its Board of Directors has approved a 3-for-2 stock split, which will be effected in the form of a 50% stock dividend to shareholders of record as of the close of business on April 24, 2006. As of March 31, 2006, the Company had approximately 45,212,607 shares of common stock outstanding. The stock split will increase the number of shares of common stock outstanding to approximately 67,818,911 shares. The expected date of distribution is May 15, 2006.
“We have experienced a consistent rise in the value of our stock as a result of the success of the Galileo and our continuing success in improving both gross and operating margins,” said Edward L. Gallup, chairman and chief executive officer. “This stock split is a result of the success of these strategies. By increasing the number of our shares in the market, we hope to make the price of our stock more accessible to investors of all levels and thereby give more investors an opportunity to participate in our company’s growth.”
The stock split is the eighth for Immucor since its initial public offering in December 1985. Most recently, the company implemented three-for- two splits in June and November 2004.
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.
For more information on Immucor, please visit our website at www.immucor.com.
Statements contained in this press release that are not statements of historical fact are “forward-looking statements” as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor’s expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as “plans,” “expects,” “believes,” “anticipates,” “estimates,” “projects,” “will,” “should” and other words of similar meaning. Factors that could cause actual results to differ materially from those expressed in any forward- looking statement include the following: the decision of customers to defer capital spending, increased competition in the sale of instruments and reagents, product development or regulatory obstacles, changes in interest rates and general economic conditions Further risks are detailed in Immucor’s filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on any forward-looking statements. Immucor assumes no obligation to update any forward-looking statements.
Immucor, Inc.
CONTACT: Edward Gallup of Immucor, Inc., +1-770-441-2051
Web site: http://www.immucor.com//